Esophageal ECM Hydrogel Coating for Non-Invasive Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for esophageal inflammation and Barrett's esophagus, such as endoscopic resection and radiofrequency ablation, are invasive and limited to late-stage diseases, lacking effective methods for early-stage intervention and prevention.
Innovation Solution
Administration of an extracellular matrix (ECM) hydrogel with specific gelation, viscosity, and stiffness properties for topical application in the esophagus, which coats the mucosa and inhibits inflammation and reduces stricture.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endoscopic resection and radiofrequency ablation are used to treat Barrett's esophagus, then late-stage disease can be treated, but the treatments are invasive and cannot be used for early-stage intervention
Solution Approach 1:
The invention changes the physical and chemical parameters of the treatment approach by using a hydrogel with specific gelation temperature (37°C), viscosity (1-100 Pa·s), and stiffness (10-600 Pa) to enable non-invasive topical application. This allows the treatment to be administered as a liquid that gels in situ, avoiding invasive procedures while maintaining therapeutic effectiveness for both early and late-stage diseases
Solution Approach 2:
The ECM hydrogel acts as an intermediary carrier that delivers bioactive molecules to the esophageal mucosa. The hydrogel matrix serves as a mediator between the administered composition and the target tissue, enabling controlled release and localized action without requiring invasive surgical intervention
2Ease of operation
If a hydrogel is administered topically to the esophagus, then non-invasive treatment is achieved, but the hydrogel must have specific gelation and mechanical properties to be effective
Solution Approach 1:
The invention specifies precise parameter ranges for the hydrogel: gelation time of 10-30 minutes at 37°C, viscosity of 1-100 Pa·s, and stiffness of 10-600 Pa. These controlled parameter changes ensure the hydrogel remains injectable during administration but forms a stable gel structure in the esophagus, achieving both ease of non-invasive administration and therapeutic effectiveness
Solution Approach 2:
The hydrogel utilizes the body's own temperature (37°C) to trigger gelation automatically after administration. This self-service mechanism eliminates the need for external activation or complex delivery systems, allowing the hydrogel to transition from liquid to gel state autonomously within the esophagus based on the physiological temperature
3Reliability
If ECM hydrogel with specific stiffness and gelation properties is used, then inflammation inhibition and stricture reduction are achieved, but the formulation complexity increases
Solution Approach 1:
The invention uses a composite formulation consisting of ECM hydrogel as the base material combined with anti-inflammatory cytokines and other bioactive molecules. This composite structure leverages the mechanical properties of the ECM (stiffness 10-600 Pa, gelation time 10-30 minutes) while incorporating therapeutic agents, achieving both structural integrity for non-invasive administration and biochemical efficacy for inflammation inhibition
Solution Approach 2:
The ECM hydrogel formulation serves multiple functions simultaneously: it provides the mechanical structure for non-invasive delivery, acts as a controlled-release matrix for therapeutic agents, reduces inflammation through cytokine secretion, and prevents stricture formation. This multi-functionality reduces the need for separate treatment modalities despite the complex formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ECM hydrogel effectively inhibits inflammation, mitigates esophageal stricture, and prevents the progression to adenocarcinoma by promoting anti-inflammatory cytokine secretion and epithelial cell migration.
Implementation Method 1
a time to 50% gelation of less than 30 minutes at a temperature of about 37° C.
Implementation Method 2
a flow viscosity suitable for infusion into the esophagus
Data Source
AI summary
Methods are disclosed for inhibiting esophageal inflammation in a subject, that include administering to the esophagus of the subject with esophageal inflammation a therapeutically effective amount of an extracellular matrix (ECM) hydrogel. Methods are also disclosed for reducing esophageal stricture. Compositions are disclosed that include an esophageal extracellular matrix (ECM) hydrogel.